McKesson stock stands at EUR 824.10, 7.4 percent below USD high

Published on 10/08/2026 at 19:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock was EUR 824.10 on October 8, 2026 versus EUR 813.10. Fiscal 2027 first-quarter revenue rose 7.70 percent to USD 105.38 billion.

Key points in brief

McKesson stock was EUR 824.10 at Lang & Schwarz on October 8, 2026, up 1.35 percent versus the EUR 813.10 prior close.
The USD 723.68 to USD 999.00 52-week range places the USD 925.00 NYSE quote 7.41 percent below its high.
Fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00 on October 7, 2026, according to MarketBeat.
McKesson is listed on the NYSE and is scheduled to report second-quarter fiscal 2027 results on November 4, 2026.

Aquarellbild einer Skyline mit Bürotürmen am Fluss im Sonnenuntergangslicht — Aquarellmalerei zeigt eine Stadtsilhouette am Firmensitz-Standort von McKesson Corporation ISIN US58155Q1031 bei warmem Sonnenuntergangslicht heute, Illustration mit AI erstellt.

McKesson stock (ISIN US58155Q1031) was trading at EUR 824.10 at Lang & Schwarz on October 8, 2026 at 7:05 p.m. CEST, up 1.35 percent versus the EUR 813.10 prior close. The USD 925.00 NYSE quote at 1:11 p.m. ET stood 7.41 percent below the USD 999.00 52-week high, giving the euro price a clear market-range reference.

Stock remains below yearly high

The Lang & Schwarz bid was EUR 822.40 and the ask was EUR 825.80 on October 8, 2026. The 52-week range on the NYSE ran from USD 723.68 to USD 999.00, while the USD 925.00 quote was 27.82 percent above the low.

McKesson's current euro quote is 1.35 percent above its prior close, while the primary-exchange quote was up 1.61 percent at the finance snapshot. The two figures describe different venues and currencies, so the Lang & Schwarz move remains the relevant comparison for German investors.

Revenue growth sets the operating benchmark

MarketBeat reported on August 5, 2026 that fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year and above the USD 103.88 billion consensus estimate. That operating comparison gives the current share price a measurable earnings-period anchor.

The same fiscal 2027 first-quarter report put adjusted earnings per share at USD 9.93 against a USD 9.56 consensus estimate, a USD 0.37 difference. These figures are reported for the quarter ended June 30, 2026, rather than for the October trading session.

Valuation and earnings calendar

MarketBeat reported on October 7, 2026 that Leerink Partners raised its McKesson target from USD 1,030.00 to USD 1,070.00 while maintaining an Outperform rating. The newer target is 15.68 percent above the USD 925.00 NYSE quote.

StockAnalysis lists November 4, 2026 as McKesson's next earnings date, when the company is scheduled to release second-quarter fiscal 2027 results after the market close.

Comparison with peers

McKesson: plus 1.35 percent, P/E 24.72, market capitalization USD 108.3 billion

Cardinal Health (NYSE, USD): plus 1.73 percent, P/E 32.60, market capitalization USD 55.3 billion

Cencora (NYSE, USD): plus 0.56 percent, P/E 23.70, market capitalization USD 62.1 billion

Trading level and range

McKesson's valuation sits between the two named distributors on the available P/E figures, while its USD 108.3 billion market capitalization is larger than either peer. The next scheduled reporting date gives the market a defined calendar point for comparing revenue growth and adjusted earnings with the current trading level.

Market context: Market report S&P 500.